A systematic pan-cancer analysis of PXDN as a potential target for clinical diagnosis and treatment.

Zhou X, Sun Q, Xu C, Zhou Z, Chen X, Zhu X, Huang Z, Wang W, Shi Y

Open source

DOI
10.3389/fonc.2022.952849
Published
2022
Container
Frontiers in oncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2022.952849,
  title = {A systematic pan-cancer analysis of PXDN as a potential target for clinical diagnosis and treatment.},
  author = {Zhou X and Sun Q and Xu C and Zhou Z and Chen X and Zhu X and Huang Z and Wang W and Shi Y},
  year = {2022},
  journal = {Frontiers in oncology},
  doi = {10.3389/fonc.2022.952849},
  url = {https://doi.org/10.3389/fonc.2022.952849}
}

RIS

TY  - JOUR
TI  - A systematic pan-cancer analysis of PXDN as a potential target for clinical diagnosis and treatment.
AU  - Zhou X
AU  - Sun Q
AU  - Xu C
AU  - Zhou Z
AU  - Chen X
AU  - Zhu X
AU  - Huang Z
AU  - Wang W
AU  - Shi Y
PY  - 2022
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2022.952849
UR  - https://doi.org/10.3389/fonc.2022.952849
ER  - 

APA

X, Z., Q, S., C, X., Z, Z., X, C., X, Z., Z, H., W, W., & Y, S. (2022). A systematic pan-cancer analysis of PXDN as a potential target for clinical diagnosis and treatment.. Frontiers in oncology. https://doi.org/10.3389/fonc.2022.952849

Source records